Actively Recruiting
Improving Adherence to Pulmonary Arterial Hypertension Treatment With Telemedicine and Patient Guidance A Multicenter Pre- and Post-intervention Evaluation Study
Led by University of Sao Paulo General Hospital · Updated on 2025-06-10
61
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Pulmonary arterial hypertension (PAH) is a serious and progressive condition that often leads to high rates of hospitalization and right heart failure. This research aims to evaluate whether a structured telemedicine program can improve medication adherence and overall clinical outcomes in patients with PAH who are on stable oral therapies. The study focuses on addressing the ongoing challenge of poor treatment adherence despite advances in available medications. Participants in this randomized clinical trial will be divided into two groups: one receiving biweekly teleconsultations for six months and the other receiving standard clinical care without additional remote support. The telemedicine intervention includes patient education, monitoring of medication adherence, side effect management, and motivational support, all delivered by trained healthcare professionals without changing the prescribed medication regimen. During the study, participants will be monitored through baseline and 24-week assessments, including medication adherence measured by the Martín-Bayarre-Grau scale, functional classification, six-minute walk test, brain natriuretic peptide levels, risk stratification using COMPERA 2.0 and REVEAL Lite tools, hospitalizations, mortality, and quality of life via the CAMPHOR questionnaire. The total study duration for each participant is 24 weeks, with close follow-up to assess the impact of the telemedicine support on treatment adherence and health outcomes.
CONDITIONS
Brief Title
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 65 years diagnosed with pulmonary arterial hypertension (PAH) classified as Group 1 by WHO
- On stable oral PAH therapy (such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks before joining
- Able to participate in remote teleconsultations using phone or internet
- Provided signed informed consent agreeing to participate in the study
You will not qualify if you...
- Severe cognitive or psychiatric conditions that might affect ability to follow treatment or participate
- Unable to communicate via phone or telemedicine due to technical or personal reasons
- Taking part in another interventional clinical trial that could affect study results
- Life expectancy less than six months from any cause unrelated to PAH
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 24 weeks
Participants receive biweekly teleconsultations over 24 weeks focusing on medication adherence, patient education, side effect management, and remote support for pulmonary arterial hypertension.
Biweekly teleconsultations for 24 weeks
Trial Site Locations
Total: 1 location
1
InCor - Universidade de São Paulo
São Paulo, São Paulo, Brazil, 05048000
Actively Recruiting
Research Team
C
Caio Fernandes, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here